A Novel Risk Score for Major Bleeding in Japanese Patients with Non-Valvular Atrial Fibrillation: The J-RISK AF Study-Reference-Cited by-同舟云学术

A Novel Risk Score for Major Bleeding in Japanese Patients with Non-Valvular Atrial Fibrillation: The J-RISK AF Study

Published:2024 Issue: Volume: Page:
ISSN:1340-3478
Container-title:Journal of Atherosclerosis and Thrombosis
language:en
Short-container-title:JAT

Author:

Akao Masaharu¹,Tomita Hirofumi²,Nakai Michikazu³⁴,Kodani Eitaro⁵,Suzuki Shinya⁶,Hayashi Kenshi⁷,Sawano Mitsuaki⁸,Goya Masahiko⁹,Yamashita Takeshi⁶,Fukuda Keiichi⁸,Tsuda Toyonobu⁷,Isobe Mitsuaki⁹¹⁰,Toyoda Kazunori¹¹,Miyamoto Yoshihiro³¹²,Okamura Tomonori¹³,Sasahara Yusuke³,Okumura Ken²¹⁴,

Affiliation:

1. Department of Cardiology, National Hospital Organization Kyoto Medical Center

2. Department of Cardiology, Hirosaki University Graduate School of Medicine

3. Department of Medical and Health Information Management, National Cerebral and Cardiovascular Center

4. Clinical Research Support Center, University of Miyazaki Hospital

5. Department of Cardiovascular Medicine, Nippon Medical School Tama Nagayama Hospital

6. Department of Cardiovascular Medicine, The Cardiovascular Institute

7. Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Science

8. Department of Cardiology, Keio University School of Medicine

9. Department of Cardiovascular Medicine, Tokyo Medical and Dental University

10. Sakakibara Heart Institute

11. Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center

12. Open Innovation Center, National Cerebral and Cardiovascular Center

13. Department of Preventive Medicine and Public Health, Keio University School of Medicine

14. Division of Cardiology, Saiseikai Kumamoto Hospital

Publisher

Japan Atherosclerosis Society

Link

https://www.jstage.jst.go.jp/article/jat/advpub/0/advpub_64842/_pdf

Reference26 articles.

1. 1) Hart RG, Pearce LA and Aguilar MI: Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med, 2007; 146: 857-867

2. 2) Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T and Antman EM: Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet, 2014; 383: 955-962

3. 3) Landefeld CS and Beyth RJ: Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med, 1993; 95: 315-328

4. 4) Hylek EM, Held C, Alexander JH, Lopes RD, De Caterina R, Wojdyla DM, Huber K, Jansky P, Steg PG, Hanna M, Thomas L, Wallentin L and Granger CB: Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol, 2014; 63: 2141-2147

5. 5) Ogawa H, An Y, Ishigami K, Ikeda S, Doi K, Hamatani Y, Fujino A, Ishii M, Iguchi M, Masunaga N, Esato M, Tsuji H, Wada H, Hasegawa K, Abe M, Lip GYH and Akao M: Long-term clinical outcomes after major bleeding in patients with atrial fibrillation: The Fushimi AF Registry. Eur Heart J Qual Care Clin Outcomes, 2020; 7: 163-171